A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 2, 2001, Pages 149-158

  Gallicano, Keith ^a,b,c   Khaliq, Yasmin ^a,b,c   Carignan, Germain ^a,b,c   Tseng, Alice ^a,b,c   Walmsley, Sharon ^a,b,c   Cameron, D William ^a,b,c,d  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d Axelson Biopharma Research Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RIFABUTIN; RITONAVIR; SAQUINAVIR;

ADULT; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG SAFETY; DRUG SCREENING; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANALYSIS OF VARIANCE; ANTIBIOTICS, ANTITUBERCULAR; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MYCOBACTERIUM INFECTIONS; RIFABUTIN; RITONAVIR; SAQUINAVIR;

EID: 0034883377     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.117612     Document Type: Article

References (32)

1. Interactions among drugs for HIV and opportunistic infections
2. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir
3. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients
4. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
5. Three-year follow-up and conditional outcomes survival analysis of ritonavir (RTV) plus saquinavir (SQV) therapy in HIV infection
6. Notice to readers: Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors
7. Ritonavir enables combined therapy with rifampin and saquinavir
8. Ritonavir: Clinical pharmacokinetics and interactions with other anti-HIV agents
9. Autoinduction of rifabutin metabolism in man
10. Alprazolam-ritonavir interaction: Implications for product labeling
11. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects
12. Rifabutin absorption in humans: Relative bioavailability and food effect
13. Saquinavir a review of its pharmacology and clinical potential in the management of HIV infection
14. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations
15. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis
16. Critical drug interactions with agents used for prophylaxis and treatment of Mycobacterium avium complex infections
17. Alternative regimens for the prophylaxis of Mycobacterium avium complex in acquired immunodeficiency syndrome (AIDS)
18. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis
19. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin
20. Rifabutin (ansamycin LM 427): A new rifamycin-S derivative for the treatment of mycobacterial diseases
21. Rifabutin (RBT) reduces saquinavir (SAQ) plasma levels in HIV-infected patients
22. Pharmacokinetic drug interactions with saquinavir soft gelatin capsule
23. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers
24. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers
25. The clinical pharmacokinetics of rifabutin
26. Rifabutin: A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy
27. Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome
28. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive
29. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1 infected individuals: A pharmacokinetic pilot study
30. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy